Drugs / rezatapopt
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07372625 | Feb 2026 → Mar 2027 expected | cancer | PMV Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06616636 | Jan 2025 → Aug 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06362642 | Mar → Oct 2024 | — | PMV Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06054464 | Sep → Nov 2023 | — | PMV Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05523687 | Sep → Nov 2022 | — | PMV Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05249348 | Dec 2021 → Jun 2022 | — | PMV Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04585750 | Oct 2020 → Aug 2026 overdue | HER2 positive breast carcinoma, colorectal cancer, endometrial cancer, gallbladder cancer +8 | PMV Pharmaceuticals, Inc | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rezatapopt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04585750 ↗ |
| Known as | PC14586 | “PC14586 (rezatapopt) is a small molecule designed to bind to this pocket and thus restore a p53 wild-type (p53-WT) conformation.” PMID 40608889 ↗ Nov 20255“Rezatapopt (PC14586) is a first-in-class oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.” NCT07372625 ↗ |
| Action | Restore | “Rezatapopt is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, which stabilizes p53 in its wild-type...” PMID 41740031 ↗ Feb 2026 |
| Modality | Small molecule | “First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.” NCT04585750 ↗ |
| Route | Oral | “Multiple dose levels of daily oral rezatapopt will be evaluated” NCT04585750 ↗ |
| Target | TP53 | “First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.” NCT04585750 ↗ |